Ftse Mib
34.938,90
0,00%
DAX
20.340,57
0,65%
S&P 500
5.909,03
-1,11%
NASDAQ
19.489,68
-1,89%
Bitcoin
95.669,95
-1,27%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Arcutis Biotherapeutics Inc (ARQT) Arcutis Biotherapeutics Inc (ARQT) Notizie

Arcutis Biotherapeutics Inc

ARQT
15,85
1,14 (7,75%)
08 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
06/1/202522:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202522:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
02/1/202523:26EDGAR2Form 144 - Report of proposed sale of securities
24/12/202401:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202423:02EDGAR2Form 144 - Report of proposed sale of securities
16/12/202414:00GLOBEArcutis Submits ZORYVE® (roflumilast) Cream 0.05%..
06/12/202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
03/12/202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/12/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/12/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/12/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/12/202414:00GLOBEArcutis Announces Promotions on Executive Management Team
02/12/202422:25EDGAR2Form 144 - Report of proposed sale of securities
20/11/202401:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/11/202422:25EDGAR2Form 144 - Report of proposed sale of securities
13/11/202414:00GLOBEArcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment..
06/11/202422:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202422:04EDGAR2Form 8-K - Current report
06/11/202422:00GLOBEArcutis Announces Third Quarter 2024 Financial Results and..
05/11/202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/11/202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/11/202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/11/202422:41EDGAR2Form 144 - Report of proposed sale of securities
04/11/202422:39EDGAR2Form 144 - Report of proposed sale of securities
04/11/202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
01/11/202419:51EDGAR2Form 144 - Report of proposed sale of securities
24/10/202414:00GLOBEArcutis Presents Positive Patient-Reported Outcome Data for..
23/10/202422:00GLOBEArcutis to Report Third Quarter 2024 Financial Results and..
22/10/202421:24EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
21/10/202413:00PRNCAArcutis Canada Announces Health Canada Approval of ZORYVE®..
18/10/202414:20GLOBEArcutis Announces Health Canada Approval of ZORYVE®..
04/10/202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
03/10/202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202422:31EDGAR2Form 144 - Report of proposed sale of securities
01/10/202421:32EDGAR2Form 144 - Report of proposed sale of securities
25/9/202407:00GLOBENew Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided..
24/9/202414:00GLOBEFDA Accepts Arcutis’ Supplemental New Drug Application for..
19/9/202414:00GLOBEArcutis Announces Publication of ZORYVE® (roflumilast) Cream..
05/9/202423:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
05/9/202414:00GLOBEArcutis Completes Enrollment of Phase 1b Alopecia Areata..
03/9/202419:37EDGAR2Form 144 - Report of proposed sale of securities
28/8/202414:00GLOBEArcutis Announces Positive Long-Term Results of Roflumilast..
22/8/202414:00GLOBEArcutis to Present at the Morgan Stanley 22nd Annual Global..
15/8/202412:08IHMARKETNEWSCisco Beats Estimates and Announces Restructuring, Canoo..
15/8/202403:00GLOBECORRECTION – Arcutis Announces Second Quarter 2024 Financial..
14/8/202422:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202422:03EDGAR2Form 8-K - Current report
14/8/202422:00GLOBEArcutis Announces Second Quarter 2024 Financial Results and..
Apertura: 15,06 Min: 14,955 Max: 16,20
Chiusura: 14,71

La tua Cronologia

NASDAQ
ARQT
Arcutis Biotherapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network